Sera aims to be a global leader in high-value women’s health diagnostics, delivering pivotal information to physicians to improve the health of pregnant women and newborns, and to simultaneously improve the health economics.
We believe providing an individualized risk of spontaneous premature birth and other pregnancy complications is a critical first step to improving maternal and newborn health. Sera is dedicated to improving the lives of women and babies through individualized prenatal care. Our vision is to deliver pivotal and actionable information to pregnant women, their physicians and healthcare payers to significantly improve maternal and neonatal health and to meaningfully reduce healthcare costs.
Accurately identifying women at higher risk for spontaneous preterm birth is a critical first step to addressing an early delivery’s health and economic impacts. The PreTRM® Test predicts a patient’s individual risk of spontaneous preterm delivery in asymptomatic singleton pregnancies through a single blood draw performed during weeks 18 through 20 of gestational age.
